Zacks Investment Research
29 Oct 2026, 08:46 UTC · 2h ago
Impact · against what's priced in
Prime Medicine's stock surge reflects the market reacting to FDA clearance for PM647 and the first patient dosing for PM577a. While these clinical milestones and revenue growth are positive, the accompanying increase in quarterly losses indicates a rising burn rate.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
Prime Medicine received FDA clearance for its investigational therapy PM647 for alpha-1 antitrypsin deficiency (AATD).
Priced inanalysis of recent clinical/regulatory progress
So whatFDA clearance moves the candidate into the next trial phase, potentially reducing the time to first-patient-in within the next quarter.
More positive than 92% of claims this week
Continue reading
5 related stories
FDA clearance for PM647 and the dosing of the first patient in the PM577a study provide concrete clinical progress, while revenue is expected to jump 361.6% to $5.68 million.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Prime Medicine dosed the first patient in a phase I/II study for PM577a treating H1069Q-mutated Wilson disease earlier this month.
Priced inoccurred 'earlier this month'
So whatFirst-patient dosing marks the start of the clinical timeline, with initial safety data typically expected within 6-12 months.
More positive than 76% of claims this week
Revenues for the upcoming quarterly report are expected to be $5.68 million, a 361.6% increase from the year-ago quarter.
Priced inanalysis of upcoming report expectations
So whatThe massive revenue growth suggests significant new partnership milestones or grants hitting the P&L in the next print.
More positive than 63% of claims this week
The company is expected to post a quarterly loss of $0.23 per share in its upcoming report, a 28.1% year-over-year increase.
Priced inanalysis of upcoming report expectations
So whatWidening losses indicate an increased burn rate that may necessitate capital raising or dilution before FY2027.
More negative than 71% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
Shares rose 23.2% due to FDA clearance for therapy PM647 and positive progress in its gene-editing pipeline.
More positive than 46% of ticker scores this week
The stock closed 2.1% higher in the last trading session, though overall monthly returns are negative.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
2h ago
—
PRME hasn't traded since this ran. Last close $5.36 (Oct 28); the reaction starts at the next open.
PRME chart →
